Merck's Keytruda Receives the NMPA's Approval as a 2L Treatment for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shots:
- The approval is based on P-III KEYNOTE-181 study assessing Keytruda vs CT in previously treated patients with recurrent or metastatic ESCC whose tumors expressed PD-L1 (CPS ≥10) and data from an extension of the global study in Chinese patients
- Results: Median OS (10.3 vs 6.7mos.)- in Chinese patients: median OS (12.0 vs 5.4mos.). With the approval- Keytruda is now approved for five indications across three different types of cancer in China- including 1L treatment for patients with advanced NSCLC (monothx. and in combination with CT) and as a 2L treatment for advanced melanoma
- Keytruda is an anti-PD-1 therapy- acts by increasing the ability of the body’s immune system to help detect and fight tumor cells. In Jul’2019- the US FDA has approved the therapy for the same indication based on global KEYNOTE-181 study
Click here to read full press release/ article
Ref: BusinessWire | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com